PD816
PARENTERAL NUTRITION AND RISK OF BLOODSTREAM INFECTIONS IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
C. Zambo1,2,*, A. I. O. Yahia3, T. B. A. Khalid4, A. Basendwah5, H. Ferro6, F. Alabbas7
1Clinical Nutrition, Beneficência Portuguesa Hospital, 2Clinical Nutrition, Ganep Nutrição Humana, São Paulo, Brazil, 3Departament of Pathology, College of Medicine, University of Bisha & King Abdullah Hospital, 4Departament of Pathology, College of Medicine, University of Bisha, Bisha, 5Hematology Oncology Division, Departament of Medicine,, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia, 6Departament of Medicine, Division of Critical Care Schulich School of Medicine and Dentistry, University of Western Ontario, Ontario, Canada, 7Pediatrics, Hematology and Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Rationale: Parenteral nutrition (PN) is frequently used in hematopoietic stem cell transplantation (HSCT), where bloodstream infections (BSI) are serious complications associated with increased mordibity and mortality. However, the association between PN and BSI remains uncertain. This study aimed to evaluate the impact of PN on BSI risk in adult HSCT patients.
Methods: A systematic review and meta-analysis was conducted in adult patients with hematological diseases undergoing HSCT. Studies comparing PN versus non-parenteral nutrition (non-PN) were identified through searches in PubMed, Embase and Cochrane databases, in accordance with PRISMA guidelines. The primary outcome was bloodstream infections. A random-effects meta-analysis using restricted maximum likelihood (REML) was performed.
Results: Three studies including a total of 422 patients were analyzed. PN was not significantly associated with bloodstream infections (risk ratio 1.08, 95% confidence interval 0.96-1.22, p=0.21). No heterogeneity was observed (I2=0%).
Conclusion: PN was not associated with a significant increase in bloodstream infections in adult patients with hematological diseases undergoing HSCT. These findings suggest that parenteral nutrition may be safe in this specific population, although further high-quality evidence is needed.
Disclosure of Interest: None declared
